ESMO – Talk Bio

ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions

5 days ago talkbio0Tagged 2025, ADCs, Administration occupational activities, Antibody-Drug Conjugates, Biological Markers, chemo-displacement, Datopotamab deruxtecan, Datroway, Enhertu, ESMO, HER2-positive, Limited stage (cancer stage), Malignant neoplasm of breast, Toxicity aspects, trastuzumab, Triple Negative Breast Neoplasms

ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management

CatalYm Presents Long-Term Phase 1/2a Data for Visugromab at ESMO 2025

6 days ago talkbio0Tagged CatalYm, CPI-refractory tumors, ESMO, Growth Differentiation Factor 15, Visugromab

CatalYm; Visugromab; ESMO 2025; CPI-Refractory Tumors; GDF-15

Roche’s Giredestrant Advances Oral SERD Debate at ESMO 2025

7 days ago talkbio0Tagged ER-Positive HER2-Negative Breast Cancer, ESMO, giredestrant, Oral SERD, Roche (company)

ESMO 2025; Giredestrant; Roche; Oral SERD; ER-Positive HER2-Negative Breast Cancer

Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025

1 week ago talkbio0Tagged adjuvant treatment, atezolizumab, ctDNA-guided therapy, Disease-Free Survival, ESMO, genentech, IMvigor011, Malignant neoplasm of urinary bladder, muscle-invasive bladder cancer, Overall Survival, Roche (company), Signatera, Tecentriq

Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche

Friday Five: ESMO Looms Large, Arcus’ TIGIT Revival, and J&J’s Myeloma Advances

1 week ago talkbio0Tagged 2025, Arcus Biosciences, domvanalimab, ESMO, gastroesophageal adenocarcinoma, immuno-oncology, J&J, Multiple Myeloma, oncology clinical trials, Substance with programmed cell death protein 1 inhibitor mechanism of action (substance), TIGIT antibody, zimberelimab

ESMO 2025; Arcus Biosciences; domvanalimab; TIGIT antibody; gastroesophageal adenocarcinoma; J&J; multiple myeloma; immuno-oncology; PD-1 inhibitor; zimberelimab; oncology clinical trials

AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025

2 weeks ago talkbio0Tagged Antibody-Drug Conjugates, AstraZeneca, cancer care, Datopotamab deruxtecan, Datroway, Deruxtecan, durvalumab, Enhertu, ESMO, Imfinzi, Malignant neoplasm of stomach, Malignant neoplasm of urinary bladder, Neoplasms, Overall Survival, trastuzumab, trials, Triple Negative Breast Neoplasms

AstraZeneca; ESMO 2025; cancer care; pivotal trials; oncology; Datopotamab deruxtecan (Datroway); Enhertu (trastuzumab deruxtecan); Imfinzi (durvalumab); triple-negative breast cancer; bladder cancer; gastric cancer; overall survival; antibody-drug conjugates